These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 20079036)
1. [Clinical analysis of thirteen cases of hypersensitivity reactions to carboplatin.]. Wang HB; Shen K; Yang JX; Huang HF; Li Y; Wu M; Pan LY Zhonghua Fu Chan Ke Za Zhi; 2009 Nov; 44(11):837-40. PubMed ID: 20079036 [TBL] [Abstract][Full Text] [Related]
2. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies. Robinson JB; Singh D; Bodurka-Bevers DC; Wharton JT; Gershenson DM; Wolf JK Gynecol Oncol; 2001 Sep; 82(3):550-8. PubMed ID: 11520154 [TBL] [Abstract][Full Text] [Related]
3. Incidence of Carboplatin-related hypersensitivity reactions in Japanese patients with gynecologic malignancies. Koshiba H; Hosokawa K; Kubo A; Miyagi Y; Oda T; Miyagi Y; Watanabe A; Honjo H Int J Gynecol Cancer; 2009 Apr; 19(3):460-5. PubMed ID: 19407575 [TBL] [Abstract][Full Text] [Related]
4. Outpatient rapid 4-step desensitization for gynecologic oncology patients with mild to low-risk, moderate hypersensitivity reactions to carboplatin/cisplatin. Li Q; Cohn D; Waller A; Backes F; Copeland L; Fowler J; Salani R; O'Malley D Gynecol Oncol; 2014 Oct; 135(1):90-4. PubMed ID: 25110329 [TBL] [Abstract][Full Text] [Related]
5. Clinical features of hypersensitivity reactions to carboplatin. Markman M; Kennedy A; Webster K; Elson P; Peterson G; Kulp B; Belinson J J Clin Oncol; 1999 Apr; 17(4):1141. PubMed ID: 10561172 [TBL] [Abstract][Full Text] [Related]
6. Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants' Hospital. Schwartz JR; Bandera C; Bradley A; Brard L; Legare R; Granai CO; Dizon DS Gynecol Oncol; 2007 Apr; 105(1):81-3. PubMed ID: 17157366 [TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin is a safe alternative option for patients with recurrent gynecologic cancers after hypersensitivity reaction to Carboplatin. Kolomeyevskaya NV; Lele SB; Miller A; Riebandt GC; Blum BL; Odunsi KO; Frederick PJ Int J Gynecol Cancer; 2015 Jan; 25(1):42-8. PubMed ID: 25356535 [TBL] [Abstract][Full Text] [Related]
8. Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. Polyzos A; Tsavaris N; Kosmas C; Arnaouti T; Kalahanis N; Tsigris C; Giannopoulos A; Karatzas G; Giannikos L; Sfikakis PP Oncology; 2001; 61(2):129-33. PubMed ID: 11528251 [TBL] [Abstract][Full Text] [Related]
9. Outpatient desensitization of patients with moderate (high-risk) to severe platinum hypersensitivity reactions. Vetter MH; Khan A; Backes FJ; Bixel K; Cohn DE; Copeland LJ; Fowler JM; Salani R; Li Q; O'Malley DM Gynecol Oncol; 2019 Feb; 152(2):316-321. PubMed ID: 30503265 [TBL] [Abstract][Full Text] [Related]
10. Hypersensitivity to carboplatin in children. Schiavetti A; Varrasso G; Maurizi P; Castello MA Med Pediatr Oncol; 1999 Mar; 32(3):183-5. PubMed ID: 10064185 [TBL] [Abstract][Full Text] [Related]
11. Carboplatin plus paclitaxel in the treatment of gynecologic malignancies: the Cleveland Clinic experience. Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-26-S15-29. PubMed ID: 9346218 [TBL] [Abstract][Full Text] [Related]
12. Retreatment with nedaplatin in patients with recurrent gynecological cancer after the development of hypersensitivity reaction to carboplatin. Arimoto T; Oda K; Nakagawa S; Kawana K; Tsukazaki T; Adachi K; Matsumoto Y; Yano T; Kozuma S; Taketani Y J Obstet Gynaecol Res; 2013 Jan; 39(1):336-40. PubMed ID: 22690725 [TBL] [Abstract][Full Text] [Related]
13. Drug fever induced by carboplatin-based regimens: Higher incidence in a women's hospital. Zhang X; Zhao M; Zheng C Taiwan J Obstet Gynecol; 2021 Sep; 60(5):882-887. PubMed ID: 34507666 [TBL] [Abstract][Full Text] [Related]
14. Effect of Prophylactic Extended-Infusion Carboplatin on Incidence of Hypersensitivity Reactions in Patients with Ovarian, Fallopian Tube, or Peritoneal Carcinomas. Pasternak AL; Link NA; Richardson CM; Rose PG Pharmacotherapy; 2016 Jul; 36(7):723-30. PubMed ID: 27196693 [TBL] [Abstract][Full Text] [Related]
15. Relationship between a history of systemic allergic reactions and risk of subsequent carboplatin hypersensitivity. Markman M; Zanotti K; Kulp B; Peterson G; Markman M Gynecol Oncol; 2003 Jun; 89(3):514-6. PubMed ID: 12798720 [TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of substituting nedaplatin after carboplatin hypersensitivity reactions in gynecologic malignancies. Michikami H; Minaguchi T; Ochi H; Onuki M; Okada S; Matsumoto K; Satoh T; Oki A; Yoshikawa H J Obstet Gynaecol Res; 2013 Jan; 39(1):330-5. PubMed ID: 22640034 [TBL] [Abstract][Full Text] [Related]
19. Management and preparedness for infusion and hypersensitivity reactions. Lenz HJ Oncologist; 2007 May; 12(5):601-9. PubMed ID: 17522249 [TBL] [Abstract][Full Text] [Related]
20. Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma. Ottaiano A; Tambaro R; Greggi S; Prato R; Di Maio M; Esposito G; Scala F; Barletta E; Losito S; De Vivo R; Iaffaioli VR; Pignata S Anticancer Res; 2003; 23(4):3465-8. PubMed ID: 12926091 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]